Successful intravenous thrombolysis in acute ischemic stroke after reversal of dabigatran etexilate with idarucizumab at the end of therapeutic time window

Dabigatran is a direct oral anticoagulant that is widely used for stroke prevention in patients with atrial fibrillation. We report a case of an 80-year-old stroke patient on dabigatran for permanent atrial fibrillation, who presented with an initial National Institutes of Health Stroke Scale (NIHSS...

Descripción completa

Detalles Bibliográficos
Autores principales: Vukorepa, Gorana, Deveđija, Sabina, Crnjaković, Miljenko, Karakaš, Mirna, Ćuk, Željka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305667/
https://www.ncbi.nlm.nih.gov/pubmed/32587929
http://dx.doi.org/10.4103/2452-2473.285015
_version_ 1783548511573245952
author Vukorepa, Gorana
Deveđija, Sabina
Crnjaković, Miljenko
Karakaš, Mirna
Ćuk, Željka
author_facet Vukorepa, Gorana
Deveđija, Sabina
Crnjaković, Miljenko
Karakaš, Mirna
Ćuk, Željka
author_sort Vukorepa, Gorana
collection PubMed
description Dabigatran is a direct oral anticoagulant that is widely used for stroke prevention in patients with atrial fibrillation. We report a case of an 80-year-old stroke patient on dabigatran for permanent atrial fibrillation, who presented with an initial National Institutes of Health Stroke Scale (NIHSS) of 8. Dabigatran was reversed with idarucizumab, and intravenous tissue-type plasminogen activator (IV-tPA) was administrated beginning 4 h and 28 min after the symptom onset. The patient was discharged with an NIHSS of 1. Our case is an additional proof of safety and efficiency of idarucizumab in the clinical setting of ischemic stroke before the administration of IV-tPA.
format Online
Article
Text
id pubmed-7305667
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-73056672020-06-24 Successful intravenous thrombolysis in acute ischemic stroke after reversal of dabigatran etexilate with idarucizumab at the end of therapeutic time window Vukorepa, Gorana Deveđija, Sabina Crnjaković, Miljenko Karakaš, Mirna Ćuk, Željka Turk J Emerg Med Case Report Dabigatran is a direct oral anticoagulant that is widely used for stroke prevention in patients with atrial fibrillation. We report a case of an 80-year-old stroke patient on dabigatran for permanent atrial fibrillation, who presented with an initial National Institutes of Health Stroke Scale (NIHSS) of 8. Dabigatran was reversed with idarucizumab, and intravenous tissue-type plasminogen activator (IV-tPA) was administrated beginning 4 h and 28 min after the symptom onset. The patient was discharged with an NIHSS of 1. Our case is an additional proof of safety and efficiency of idarucizumab in the clinical setting of ischemic stroke before the administration of IV-tPA. Wolters Kluwer - Medknow 2020-05-27 /pmc/articles/PMC7305667/ /pubmed/32587929 http://dx.doi.org/10.4103/2452-2473.285015 Text en Copyright: © 2020 Turkish Journal of Emergency Medicine http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Case Report
Vukorepa, Gorana
Deveđija, Sabina
Crnjaković, Miljenko
Karakaš, Mirna
Ćuk, Željka
Successful intravenous thrombolysis in acute ischemic stroke after reversal of dabigatran etexilate with idarucizumab at the end of therapeutic time window
title Successful intravenous thrombolysis in acute ischemic stroke after reversal of dabigatran etexilate with idarucizumab at the end of therapeutic time window
title_full Successful intravenous thrombolysis in acute ischemic stroke after reversal of dabigatran etexilate with idarucizumab at the end of therapeutic time window
title_fullStr Successful intravenous thrombolysis in acute ischemic stroke after reversal of dabigatran etexilate with idarucizumab at the end of therapeutic time window
title_full_unstemmed Successful intravenous thrombolysis in acute ischemic stroke after reversal of dabigatran etexilate with idarucizumab at the end of therapeutic time window
title_short Successful intravenous thrombolysis in acute ischemic stroke after reversal of dabigatran etexilate with idarucizumab at the end of therapeutic time window
title_sort successful intravenous thrombolysis in acute ischemic stroke after reversal of dabigatran etexilate with idarucizumab at the end of therapeutic time window
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305667/
https://www.ncbi.nlm.nih.gov/pubmed/32587929
http://dx.doi.org/10.4103/2452-2473.285015
work_keys_str_mv AT vukorepagorana successfulintravenousthrombolysisinacuteischemicstrokeafterreversalofdabigatranetexilatewithidarucizumabattheendoftherapeutictimewindow
AT deveđijasabina successfulintravenousthrombolysisinacuteischemicstrokeafterreversalofdabigatranetexilatewithidarucizumabattheendoftherapeutictimewindow
AT crnjakovicmiljenko successfulintravenousthrombolysisinacuteischemicstrokeafterreversalofdabigatranetexilatewithidarucizumabattheendoftherapeutictimewindow
AT karakasmirna successfulintravenousthrombolysisinacuteischemicstrokeafterreversalofdabigatranetexilatewithidarucizumabattheendoftherapeutictimewindow
AT cukzeljka successfulintravenousthrombolysisinacuteischemicstrokeafterreversalofdabigatranetexilatewithidarucizumabattheendoftherapeutictimewindow

Ejemplares similares